Overview

Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e)

Status:
Completed
Trial end date:
2016-08-31
Target enrollment:
0
Participant gender:
All
Summary
The goal of the study is to determine whether providing early treatment with a glucocorticoid drug, called methylprednisolone, will improve survival in critically ill patients with severe community-acquired pneumonia (CAP). Pneumonia develops when bacteria and other agents invade the lungs. The body's immune system creates a response to produce inflammation to kill the bacteria. A moderate amount of inflammation is beneficial. But, in patients sick enough to be admitted to the ICU, inflammation is frequently out of control. When the body cannot regulate inflammation vital organs (brain, heart, lung, kidney, liver) may be damaged, contributing to death or residual organ damage for those who survive. Glucocorticoids help reduce inflammation. Recent studies have shown that when the body is unable to produce sufficient amounts of glucocorticoids, inflammation can get out of control. Under these circumstances, glucocorticoids given in small doses may help aid the body's ability to reduce inflammation and improve recovery. In a small preliminary trial, glucocorticoid treatment, in addition to standard antibiotic treatment, sped up recovery from pneumonia. It also decreased the length of hospital stay, and increased survival. This Cooperative Studies Program (CSP) study will be the first large-scale, prospective, randomized clinical trial evaluating whether or not this treatment improves recovery. In this study, at each site, patients with severe CAP will be assigned to one of two treatment groups. One group will receive methylprednisolone and the other will receive a placebo (an inert substance that will look like the drug). The investigators have chosen a total duration of treatment of 20 days (7 days full dose followed by slow reduction over 13 days) to prevent relapse of inflammation and allow the body to recover its own ability to produce glucocorticoid. All patients will also receive standardized management of CAP in accordance with current practice guidelines. The study will take into consideration when assigning the treatment each participating site, and whether or not the patient requires mechanical ventilation at the time of assignment. Patients will be followed clinically for 180 days. The primary outcome is all cause 60-day mortality. Secondary outcomes are (1) in-hospital morbidity-mortality, including ventilator-free days, multiorgan dysfunction syndrome (MODS)-free days, duration of ICU and hospital stay, and hospital discharge; and (2) posthospital discharge morbidity-mortality, including cardiovascular complications, functional and general health status in the first 180 days, rehospitalization, and mortality at 1 year. Serial blood samples will also be collected and stored for future translational research relating longitudinal inflammation markers to clinical outcomes. This study will advance knowledge on the relationship between inflammation and long-term outcome in severe CAP.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
VA Office of Research and Development
Treatments:
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Criteria
Inclusion Criteria:

- Patient's origin. Patients are classified as having Community Acquired Pneumonia (CAP)
if they are admitted directly from outside the hospital, including private residence,
nursing home, rehabilitation center, other long-term care facility (health
care-associated pneumonia (HCAP)).

- Clinical diagnosis of CAP.

- Have radiographically confirmed pneumonia (new or progressive pulmonary infiltrate(s)
on chest radiograph or chest computed tomography scan consistent with bacterial
pneumonia) AND have acute illness ( <=7 days' duration) with at least three of the
following clinical signs or symptoms consistent with a lower respiratory tract
infection:

New or increased cough Purulent sputum or change in sputum character Auscultatory findings
consistent with pneumonia (e.g., rales, egophony, findings of consolidation) Dyspnea,
tachypnea, or hypoxemia (O2 saturation <90% on room air or PaO2 <60 mmHg) Fever >= 38 C
oral (>=38.5 C rectally or tympanically) or hypothermia (<=36 C) White blood cell count
greater than 10,000 cells/mm3 or less than 4,000 cells/mm3 Greater than 15% immature
neutrophils (bands) irrespective of WBC count

- Diagnosis of severe CAP. Pneumonia of sufficient severity to require admission to the
ICU (including intermediate care unit) and meeting >=1 major or >= 3 minor modified
Infectious Diseases Society of America (IDSA)/American

Thoracic Society (ATS) criteria.:

- 1 Major Criteria

1. Use of invasive or noninvasive mechanical ventilation

2. Vasopressors for shock despite adequate fluid resuscitation

3. Arterial pH < 7.30 -OR >=3 Minor Criteria

1. New onset of confusion or disorientation

2. Hypothermia (core temperature <=36 C)

3. Respiratory rate >=30 breaths/min

4. Hypotension requiring aggressive fluid resuscitation

5. Uremia (BUN >=20 mg/dL)

6. PaO2: FiO2 ratio <=250 or SaO2:FiO2 ratio <=250

7. Leukopenia (WBC count < 4000 cells/mm3)

8. Platelet count < 100,000 cells/mm3 or > 400,000 cells/mm3

9. Multilobar infiltrates

Exclusion Criteria:

- Patient's age 17 years or younger.

- Vasopressor-dependent shock requiring moderate-to-high dose vasopressor (i.e.,
norepinephrine >=0.3 mcg/Kg/min) treatment for greater than 2 hours in patient
that is adequately fluid-resuscitated (at least 4 liters of crystalloids) WITH
central venous pressure (CVP) equal to or greater than 8 mm Hg for nonventilated
patients and equal to or greater than 12 mm Hg for ventilated patients. (See
explanation below)*

- Major gastrointestinal bleeding requiring transfusion of 5 units or more of
packed red blood cells within 3 months of current hospitalization.

- Any condition requiring 20 mg of prednisone equivalent/day for greater than 14
days, over the last 3 months.

- Chronic obstructive pulmonary disease (COPD) with acute exacerbation requiring
glucocorticoid treatment at hospital admission. Patients with short-term
glucocorticoid use (e.g., methylprednisolone up to 300 mg within 5 days of
randomization) will not be excluded.

- Patients enrolled in another experimental (interventional) protocol.

- Pregnancy, confirmed by urine or serum test.

- Presence of postobstructive pneumonia or cystic fibrosis.

- Clinical history consistent with aspiration of gastric content (i.e., loss of
consciousness or seizure).

- Active tuberculosis or fungal infection.

- Moribund patient (i.e., not expected to live more than 24 h) or with recent
(within 7 days) cardiopulmonary arrest, or with (known or suspected) irreversible
cessation of all brain function, or comfort measure status.

- Presence of preexisting medical condition that is irreversible and expected to
be fatal within 3 months.

- Patients with severe immunosuppression (i.e., HIV with CD4 <200),
neutropenia (less than 1000 neutrophils) not related to pneumonia, acute
burn injury, or receiving immunosuppressive or cytotoxic therapy for any
reason.

- Chronic severe cognitive impairment caused by dementia or central nervous
system pathologies (tumor, cerebro-vascular accident, infections, or head
injuries) as defined by the site investigator by obtaining medical history
and reviewing medical record.

- The physician doesn't feel the patient is a viable candidate for the study
(e.g., presence of hypersensitivity or previous severe adverse reaction to
cosyntropin or any glucocorticoid, history of adrenal insufficiency or
chronic systemic steroid use placing the patient at risk for relative
adrenal insufficiency).